Cartesian Therapeutics Inc (RNAC) Actualités

Cartesian Therapeutics Announces New Employment Inducement Grant

FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Form 8-K - Current report

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Form 8-K - Current report

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form 4 - Statement of changes in beneficial ownership of securities

Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deepening responses...

Form POS AM - Post-Effective amendments for registration statement

Form POS AM - Post-Effective amendments for registration statement

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness